Skip to Content
Merck
All Photos(3)

Key Documents

P1722

Sigma-Aldrich

Potassium citrate tribasic monohydrate

meets USP testing specifications

Synonym(s):

Citric acid tripotassium salt, Tripotassium citrate

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
HOC(COOK)(CH2COOK)2 · H2O
CAS Number:
Molecular Weight:
324.41
Beilstein:
3924344
EC Number:
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
NACRES:
NA.21

Agency

USP/NF
meets USP testing specifications

Quality Level

form

crystals

mp

275 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

SMILES string

O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

1S/C6H8O7.3K.H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;1H2/q;3*+1;/p-3

InChI key

PJAHUDTUZRZBKM-UHFFFAOYSA-K

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Potassium citrate tribasic monohydrate (KCTM) is a potassium salt that has been reported to be efficient in forming aqueous two-phase system (ATPS) with UCON 50-HB-5100, a random copolymer. This product is a high quality pharmacopoeia product that meets the testing specifications of USP (United States Pharmacopoeia). It can be employed in research and pilot studies.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

(Liquid+ liquid) equilibria of polymer-salt aqueous two-phase systems for laccase partitioning: UCON 50-HB-5100 with potassium citrate and (sodium or potassium) formate at 23?C.
Lladosa E, et al.
The Journal of Chemical Thermodynamics, 55, 166-171 (2012)
Clay Mechlin et al.
Journal of endourology, 25(9), 1541-1545 (2011-08-06)
Oral citrate supplements have been shown to decrease kidney stone recurrence rates in both laboratory and clinical studies. The taste of the citrate supplements, however, is poor, and long-term compliance is low. Our objective was to determine if Splenda(®) added
Chao-Yang Duan et al.
International journal of nanomedicine, 8, 909-918 (2013-03-08)
The property changes of urinary nanocrystallites in 13 patients with calcium oxalate (CaOx) stones were studied before and after ingestion of potassium citrate (K3cit), a therapeutic drug for stones. The analytical techniques included nanoparticle size analysis, transmission electron microscopy, X-ray
Donna J Claes et al.
Pediatric nephrology (Berlin, Germany), 27(11), 2031-2038 (2012-01-28)
Cystinuria is a relatively uncommon cause of pediatric stone disease, but has significant morbidity if not properly controlled because of its significant stone recurrence rate. Cystinuria is caused by the inability of the renal tubules to reabsorb filtered cystine, which
Pierre Cochat et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 27(5), 1729-1736 (2012-05-02)
Primary hyperoxaluria Type 1 is a rare autosomal recessive inborn error of glyoxylate metabolism, caused by a deficiency of the liver-specific enzyme alanine:glyoxylate aminotransferase. The disorder results in overproduction and excessive urinary excretion of oxalate, causing recurrent urolithiasis and nephrocalcinosis.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service